Sunshine Biopharma (SBFMW) Short term Debt (2018 - 2019)

Sunshine Biopharma (SBFMW) reported Short term Debt of $27541.0 for Q3 2019, down 1.18% quarter-over-quarter from $27869.0 in Q2 2019.

Sunshine Biopharma (SBFMW) Short term Debt (2018 - 2019) Analysis & Trends

Sunshine Biopharma has reported Short term Debt for 2 years, with the latest figure at $27541.0 in Q3 2019.

For the quarter ending Q3 2019, Short term Debt changed N/A year-over-year to $27541.0; the trailing twelve-month figure through Sep 2019 stood at $27541.0 (changed N/A YoY), and the FY2018 full-year result was $20871.0, changed N/A from the prior year.
Short term Debt for Q3 2019 stood at $27541.0, down from $27869.0 in the prior quarter.
The five-year high for Short term Debt was $59558.0 in Q1 2019, with the low at $20871.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.97 Bn	36.23 Bn	1.97 Bn
2	Zoetis	33.59 Bn	31.65 Bn	1.62 Bn
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn
4	Neurocrine Biosciences	16.10 Bn	14.78 Bn	800.70 Mn
5	Aurora Cannabis	15.56 Bn	15.47 Bn	21.72 Mn
6	Elanco Animal Health	12.04 Bn	11.61 Bn	785.00 Mn
7	Alkermes	7.36 Bn	6.84 Bn	-116.06 Mn
8	Lantheus Holdings	6.74 Bn	6.24 Bn	230.92 Mn
9	Liquidia	6.27 Bn	6.04 Bn	121.79 Mn
10	Sunshine Biopharma	-	-	2.18 Mn

Download Data